IMMUNOHISTOCHEMISTRY, BCL-2

The IHC – BCL-2 test is an immunohistochemistry-based diagnostic assay used to detect BCL-2 protein expression in tissue samples. BCL-2 (B-cell lymphoma 2) is a protein involved in regulating cell survival and apoptosis (programmed cell death). Overexpression of BCL-2 allows abnormal cells to survive longer than normal, contributing to the development and progression of several cancers.

This test is widely used in pathology and oncology to help diagnose and classify lymphomas, leukemias, and various solid tumors. BCL-2 expression is especially important in identifying follicular lymphoma, where abnormal BCL-2 positivity is a characteristic finding.

Benefits of the Test

• Helps diagnose lymphoma and hematological malignancies
• Assists in tumor classification and grading
• Supports evaluation of tumor aggressiveness
• Helps differentiate benign from malignant lymphoid lesions
• Aids oncologists in treatment planning and prognosis assessment

Why Doctors Recommend This Test

Doctors recommend the IHC BCL-2 test when there is suspicion of lymphoma, leukemia, or other malignant tumors. It is commonly used in:

• Diagnosis of follicular lymphoma
• Evaluation of lymph node biopsies
• Classification of hematological cancers
• Assessment of tumor survival pathways
• Oncology biopsy interpretation

BCL-2 staining is often used together with other markers such as CD10, CD20, Ki-67, BCL-6, and CD3 to improve diagnostic accuracy and tumor profiling.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting or medication restrictions are needed
• Previous pathology reports and clinical history may assist interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients with suspected lymphoma or leukemia
• Individuals with enlarged lymph nodes
• Cases requiring tumor classification and grading
• Patients undergoing oncology biopsy evaluation
• Individuals with suspected hematological malignancies

The IHC BCL-2 test is an important diagnostic tool in hematopathology and oncology. By detecting abnormal BCL-2 protein expression, it helps pathologists identify malignant cells, understand tumor behavior, and guide appropriate treatment planning.